Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Tibet Duo Rui Pharmaceutical Co Ltd banner
T

Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075

Watchlist Manager
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
Watchlist
Price: 61.89 CNY -0.48%
Market Cap: ¥5B
Write Note Create Alert Ask AI

Relative Value

The Relative Value of one Tibet Duo Rui Pharmaceutical Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 61.89 CNY, Tibet Duo Rui Pharmaceutical Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Tibet Duo Rui Pharmaceutical Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

P/S
View Details
P/E
View Details
P/OCF
View Details
P/FCFE
View Details
P/B
View Details
EV/S
View Details
EV/GP
View Details
EV/EBITDA
View Details
EV/EBIT
View Details
EV/OCF
View Details
EV/FCFF
View Details
EV/IC
View Details

Multiples Across Competitors

Competitors Multiples
Tibet Duo Rui Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
4.9B CNY 27.6 -39 -32.4 -32.4
US
Eli Lilly and Co
NYSE:LLY
990.8B USD 15.2 48 32.3 34.4
US
Johnson & Johnson
NYSE:JNJ
590.6B USD 6.3 22 15.3 18.8
CH
Roche Holding AG
SIX:ROG
286.4B CHF 4.7 30.4 12.8 15
UK
AstraZeneca PLC
LSE:AZN
232.4B GBP 5.5 34.2 16.3 23.8
CH
Novartis AG
SIX:NOVN
236.9B CHF 5.4 21.8 13.4 17.2
US
Merck & Co Inc
NYSE:MRK
298.8B USD 4.6 16.3 10.2 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.8 11.5
US
Pfizer Inc
NYSE:PFE
157.2B USD 2.5 20.2 7.5 10
US
Bristol-Myers Squibb Co
NYSE:BMY
122.1B USD 2.5 17.3 6.8 8.7
P/E Multiple
Earnings Growth PEG
CN
T
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
Average P/E: 24.8
Negative Multiple: -39 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
30.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
34.2
38%
0.9
CH
Novartis AG
SIX:NOVN
21.8
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.3
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
7%
1.9
US
Pfizer Inc
NYSE:PFE
20.2
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
T
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
Average EV/EBITDA: 45.8
Negative Multiple: -32.4 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.3
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.3
2%
7.7
CH
Roche Holding AG
SIX:ROG
12.8
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
16.3
10%
1.6
CH
Novartis AG
SIX:NOVN
13.4
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.2
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
7%
1.4
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.8
-13%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
T
Tibet Duo Rui Pharmaceutical Co Ltd
SZSE:301075
Average EV/EBIT: 98.7
Negative Multiple: -32.4 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.4
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.8
6%
3.1
CH
Roche Holding AG
SIX:ROG
15
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
23.8
23%
1
CH
Novartis AG
SIX:NOVN
17.2
12%
1.4
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
8%
1.4
US
Pfizer Inc
NYSE:PFE
10
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
-6%
N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 317,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.